Berkshire Hathaway Equity Method Investments increased by 0.8% to $25.52B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 15.3%, from $30.13B to $25.52B. Over 3 years (FY 2021 to FY 2024), Equity Method Investments shows an upward trend with a 21.5% CAGR.
An increase indicates strategic expansion through partnerships or joint ventures, while a decrease may signal divestments or impairment.
These are investments in entities where the company exercises significant influence but does not have full control. The...
Varies significantly based on corporate strategy; common in healthcare companies that partner with biotech startups or specialized diagnostic firms.
equity_method_investments| Q4 '21 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $17.38B | $28.71B | $28.05B | $26.40B | $27.49B | $27.50B | $29.07B | $29.59B | $30.07B | $30.13B | $31.13B | $31.14B | $25.32B | $25.52B |
| QoQ Change | — | +65.3% | -2.3% | -5.9% | +4.1% | +0.0% | +5.7% | +1.8% | +1.6% | +0.2% | +3.3% | +0.0% | -18.7% | +0.8% |
| YoY Change | — | — | +61.4% | — | — | -4.2% | +3.6% | +12.1% | +9.4% | +9.6% | +7.1% | +5.3% | -15.8% | -15.3% |